1-5 of 5
Thomas P. Cirrito, PhD
Close
Sort by
Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD
Journal: Blood
Blood (2012) 120 (21): 3625.
https://doi.org/10.1182/blood.V120.21.3625.3625
Published: 2012
Journal Articles

SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma.

Christopher L. Brooks, PhD, Thomas P. Cirrito, PhD, Kenneth Hoberman, Eric Rowinsky, MD
Journal: Blood
Blood (2012) 120 (21): 2768.
https://doi.org/10.1182/blood.V120.21.2768.2768
Published: 2012
Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD
Journal: Blood
Blood (2011) 118 (21): 2588.
https://doi.org/10.1182/blood.V118.21.2588.2588
Published: 2011
Journal Articles

Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, An IL-3Rα Targeted Drug,

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Christopher L. Brooks, PhD, Jairo Baquero-Buitrago, MSc, Crystal Cruz, Isabelita Vengco, Francesca Montanari, MD, Enrica Marchi, MD, Ph.D., Luigi Scotto, Ph.D., Thomas P. Cirrito, PhD, Ivan Bergstein, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3737.
https://doi.org/10.1182/blood.V118.21.3737.3737
Published: 2011
Journal Articles

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Jen Sing Liu, PhD, Steven M. Kornblau, MD, Margarite Grable, Il-Ran Hwang, Gautam Borthakur, MD, Allison Mankin, Carol Bivins, Guillermo Garcia-Manero, MD, Tapan Kadia, MD, David Harris, Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, Robert Niecestro, PhD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD
Journal: Blood
Blood (2010) 116 (21): 3298.
https://doi.org/10.1182/blood.V116.21.3298.3298
Published: 2010